在遗传性血管的长期预防中使用减弱的雄激素的德尔菲共识:AURA项目
Eunice Dias de Castro1,2, Luís Miguel Cardoso3,4,5,6, João Jácome de Castro7
1Allergy and Clinical Immunology Department, São João Local Health Unit, Porto, Portugal.
Clinical and translational allergy
|November 11, 2025
概括
这项研究提供了使用达纳在遗传性血管 (HAE) 长期预防 (LTP) 的专家建议. 它提供了关于处方,监测和停止治疗的指导,以确保更安全的患者治疗.
科学领域:
- 临床免疫学临床免疫学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 丹纳,一种减弱的雄激素,一直是遗传性血管炎 (HAE) 的长期预防 (LTP) 选择.
- 雄激素副作用限制了达纳的使用,促使人们转向使用较新的药物进行二线治疗.
- 随着HAE治疗指南的不断变化,需要更新达纳管理的框架.
研究的目的:
- 建立专家的共识,达纳在HAE长期预防中的作用.
- 制定达纳佐尔处方,监测和停止使用的指导方针.
- 为满足HAE中标准化达纳管理协议的需求.
主要方法:
- 采用了两轮的Delphi方法.
- 一个由专家组成的指导委员会根据证据定义了陈述.
- 一个由23名HAE管理专家组成的小组投票达成共识.
主要成果:
- 在HAE LTP.中,针对达纳的处方,监测和中止,产生了46条建议.
- 在禁忌,监测参数和治疗调整方面达成了共识.
- 七个建议专门针对HAE患者的达纳止药策略.
结论:
- 德尔菲研究填补了HAE中达纳的临床指导中的关键缺口.
- 这份共识文件有助于标准化达纳停药方案.
- 这为优化患者获得安全有效的HAE治疗提供了一个框架.
相关概念视频
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Aortic Regurgitation III: Medical Management
383
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
383
Angina IV: Management
223
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
223


